MCID: PRS038
MIFTS: 62

Personality Disorder

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Personality Disorder

MalaCards integrated aliases for Personality Disorder:

Name: Personality Disorder 12 29 15
Personality Disorders 55 43 73
Character Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1510
ICD9CM 35 301.8 301.89
ICD10 33 F60 F60.9

Summaries for Personality Disorder

MedlinePlus : 43 Personality disorders are a group of mental illnesses. They involve long-term patterns of thoughts and behaviors that are unhealthy and inflexible. The behaviors cause serious problems with relationships and work. People with personality disorders have trouble dealing with everyday stresses and problems. They often have stormy relationships with other people. The cause of personality disorders is unknown. However, genes and childhood experiences may play a role. The symptoms of each personality disorder are different. They can mild or severe. People with personality disorders may have trouble realizing that they have a problem. To them, their thoughts are normal, and they often blame others for their problems. They may try to get help because of their problems with relationships and work. Treatment usually includes talk therapy and sometimes medicine.

MalaCards based summary : Personality Disorder, also known as personality disorders, is related to avoidant personality disorder and schizoid personality disorder, and has symptoms including photophobia, restlessness and personality changes. An important gene associated with Personality Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Peptide ligand-binding receptors and Circadian entrainment. The drugs Fluvoxamine and Citalopram have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and amygdala, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A disease of mental health that involve long-term patterns of thoughts and behaviors that cause serious problems with relationships and work.

Wikipedia : 76 Personality disorders (PD) are a class of mental disorders characterized by enduring maladaptive... more...

Related Diseases for Personality Disorder

Diseases in the Personality Disorder family:

Multiple Personality Disorder

Diseases related to Personality Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 198)
# Related Disease Score Top Affiliating Genes
1 avoidant personality disorder 34.3 MAOA SLC6A4 TPH1
2 schizoid personality disorder 34.2 HTR1A HTR2A
3 dependent personality disorder 34.0 DRD4 MAOA
4 antisocial personality disorder 33.0 ALDH2 ANKK1 COMT DRD2 HTR1B MAOA
5 borderline personality disorder 33.0 AVPR1A BDNF COMT HTR1A HTR1B HTR2A
6 intermittent explosive disorder 32.9 HTR1A PRL SLC6A4
7 impulse control disorder 30.7 ANKK1 DRD2 DRD4
8 conduct disorder 30.6 ALDH2 COMT DRD2 DRD4 MAOA SLC6A3
9 dysthymic disorder 30.5 HTR2A MAOA SLC6A4
10 depression 30.5 BDNF HTR1A HTR2A HTR2C MAOA SLC6A4
11 social phobia 30.5 DRD2 HTR1A MAOA PRL SLC6A4
12 agoraphobia 30.4 HTR1A MAOA SLC6A4
13 anxiety 30.2 BDNF COMT HTR1A HTR2A HTR2C MAOA
14 bulimia nervosa 30.2 BDNF COMT HTR1B HTR2A SLC6A4
15 cocaine dependence 30.1 DRD2 SLC6A3 SLC6A4
16 eating disorder 30.0 BDNF COMT DRD2 HTR2C SLC6A3 SLC6A4
17 anorexia nervosa 30.0 BDNF COMT HTR2A PRL SLC6A4
18 alexithymia 30.0 ANKK1 COMT DRD2 HTR1A SLC6A4
19 atypical depressive disorder 29.9 HTR2A MAOA SLC6A4
20 fibromyalgia 29.9 COMT HTR2A PRL SLC6A4
21 chronic fatigue syndrome 29.9 COMT HTR1A HTR2A MAOA SLC6A4
22 kleptomania 29.8 HTR1A MAOA SLC6A4
23 panic disorder 29.7 BDNF COMT HTR1A HTR2A HTR2C MAOA
24 asperger syndrome 29.7 AVPR1A BDNF SLC6A4
25 post-traumatic stress disorder 29.7 BDNF COMT DRD2 HTR2A MAOA SLC6A4
26 opiate dependence 29.7 DRD2 SLC6A4 TPH1
27 postpartum depression 29.7 BDNF COMT MAOA PRL SLC6A4
28 brain injury 29.7 BDNF COMT DRD2
29 sexual disorder 29.6 HTR1A PRL SLC6A4
30 substance dependence 29.6 BDNF DRD2 DRD4 HTR1B MAOA SLC6A3
31 bipolar i disorder 29.6 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
32 drug dependence 29.6 ANKK1 BDNF DRD2 SLC6A4
33 delusional disorder 29.5 DRD2 DRD4
34 pathological gambling 29.5 DRD2 DRD4 HTR2A MAOA SLC6A3 SLC6A4
35 schizoaffective disorder 29.5 BDNF COMT DRD2 HTR2A PRL SLC6A4
36 schizophreniform disorder 29.5 COMT DRD2 PRL
37 paranoid schizophrenia 29.5 BDNF COMT HTR2A MAOA SLC6A4
38 separation anxiety disorder 29.5 DRD4 PRL SLC6A3
39 endogenous depression 29.5 BDNF HTR1A HTR2A MAOA SLC6A4 TPH1
40 traumatic brain injury 29.4 BDNF COMT DRD2
41 autism spectrum disorder 29.4 AVPR1A BDNF HTR2A SLC6A4
42 mental depression 29.4 BDNF COMT HTR1A HTR2A HTR2C MAOA
43 generalized anxiety disorder 29.4 BDNF COMT DRD2 HTR1A HTR2A MAOA
44 cocaine abuse 29.3 DRD2 PRL SLC6A3 SLC6A4
45 substance abuse 29.3 BDNF COMT DRD2 DRD4 HTR1B MAOA
46 heroin dependence 29.2 ANKK1 BDNF DRD2 DRD4
47 bipolar disorder 29.1 BDNF COMT DRD2 DRD4 HTR1A HTR2A
48 disease of mental health 29.1 BDNF COMT DRD2 DRD4 HTR1A HTR2A
49 schizophrenia 29.1 BDNF COMT DRD2 DRD4 HTR1A HTR1B
50 mood disorder 29.0 BDNF COMT DRD2 DRD4 HTR1A HTR1B

Comorbidity relations with Personality Disorder via Phenotypic Disease Network (PDN): (show all 14)


Acute Cystitis Alzheimer Disease
Anxiety Deficiency Anemia
Dependent Personality Disorder Dysthymic Disorder
Generalized Anxiety Disorder Heart Disease
Hypertension, Essential Hypothyroidism
Major Depressive Disorder Parkinson Disease, Late-Onset
Protein-Energy Malnutrition Schizophreniform Disorder

Graphical network of the top 20 diseases related to Personality Disorder:



Diseases related to Personality Disorder

Symptoms & Phenotypes for Personality Disorder

UMLS symptoms related to Personality Disorder:


photophobia, restlessness, personality changes, pseudobulbar behavioral symptoms, sleep disturbances

MGI Mouse Phenotypes related to Personality Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.28 ALDH2 AVPR1A BDNF COMT DRD2 DRD4
2 homeostasis/metabolism MP:0005376 10.07 ALDH2 AVPR1A BDNF COMT DRD2 DRD4
3 cardiovascular system MP:0005385 10.02 ALDH2 AVPR1A COMT DRD2 HTR1A HTR1B
4 endocrine/exocrine gland MP:0005379 10.02 ALDH2 AVPR1A BDNF COMT DRD2 HTR1B
5 integument MP:0010771 9.76 ALDH2 BDNF DRD2 HTR2C PRL SLC6A3
6 muscle MP:0005369 9.61 ALDH2 AVPR1A DRD2 HTR1B HTR2A HTR2C
7 nervous system MP:0003631 9.4 ALDH2 AVPR1A BDNF COMT DRD2 DRD4

Drugs & Therapeutics for Personality Disorder

Drugs for Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 262)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluvoxamine Approved, Investigational Phase 4,Phase 3,Not Applicable 54739-18-3 3404 5324346
2
Citalopram Approved Phase 4,Phase 3,Phase 2,Not Applicable 59729-33-8 2771
3
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 54910-89-3 3386
4
Risperidone Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 106266-06-2 5073
5
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
6
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 113-45-1 4158
7
Cycloserine Approved Phase 4,Phase 3,Phase 2,Not Applicable 68-41-7 6234 401
8
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 61869-08-7 43815
9
Clomipramine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 303-49-1 2801
10
Norepinephrine Approved Phase 4,Phase 3,Not Applicable 51-41-2 439260
11
Ethanol Approved Phase 4,Phase 3,Phase 2,Not Applicable 64-17-5 702
12
Guanfacine Approved, Investigational Phase 4,Phase 2,Not Applicable 29110-47-2 3519
13
Lamotrigine Approved, Investigational Phase 4,Phase 2 84057-84-1 3878
14
Ondansetron Approved Phase 4,Phase 2 99614-02-5 4595
15
Olanzapine Approved, Investigational Phase 4,Phase 3,Not Applicable 132539-06-1 4585
16
Sertraline Approved Phase 4,Phase 3,Phase 2,Not Applicable 79617-96-2 68617
17
Topiramate Approved Phase 4,Phase 3 97240-79-4 5284627
18
Haloperidol Approved Phase 4 52-86-8 3559
19
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
20
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
21
Propranolol Approved, Investigational Phase 4 525-66-6 4946
22
Naratriptan Approved, Investigational Phase 4 121679-13-8, 143388-64-1 4440
23
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
24
Maleic acid Experimental Phase 4,Phase 3 110-16-7 444266
25 Omega 3 Fatty Acid Phase 4,Phase 2,Phase 3
26 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Anti-Anxiety Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
31 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Antidepressive Agents, Second-Generation Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Cytochrome P-450 CYP2C19 Inhibitors Phase 4,Phase 3,Not Applicable
37 Cytochrome P-450 CYP1A2 Inhibitors Phase 4,Phase 3,Not Applicable
38 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Cholinergic Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
41 Muscarinic Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
42 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Parasympatholytics Phase 4,Phase 3,Phase 2,Not Applicable
45 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Serotonin Antagonists Phase 4,Phase 2,Phase 1,Not Applicable
50 Dopamine Antagonists Phase 4,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 647)
# Name Status NCT ID Phase Drugs
1 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder Unknown status NCT00437099 Phase 4 Omacor®;Placebo
2 Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD) Unknown status NCT00743834 Phase 4 Luvox CR
3 Treatment Youth With Obsessive-Compulsive Disorder Unknown status NCT00708240 Phase 4 Escitalopram
4 Reduction of Cardiovascular Risk in Severe Mental Illness Unknown status NCT01182012 Phase 4
5 Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder Completed NCT00634062 Phase 4 Lamotrigine;Placebo
6 Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder Completed NCT00533117 Phase 4 Fluoxetine
7 Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder Completed NCT00204347 Phase 4 risperidone
8 Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder Completed NCT00834834 Phase 4 Fluoxetine;Citalopram
9 Effects of Comorbid Personality Disorder on the Treatment of Bipolar I Disorder Completed NCT00178061 Phase 4
10 Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder Completed NCT02194075 Phase 4 Fluvoxamine+Methylphenidate hydrochloride;Fluvoxamine+sugar pill
11 D-Cycloserine as an Adjunct to Internet-CBT for OCD Completed NCT01649895 Phase 4 D-Cycloserine;Placebo
12 Ondansetron Augmentation in Treatment-resistant OCD Completed NCT01303536 Phase 4 Ondansetron
13 Deep Brain Stimulation for Obsessive Compulsive Disorder (OCD PMCF) Completed NCT01135745 Phase 4
14 Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder Completed NCT00854919 Phase 4 atypical antipsychotic drug
15 Ondansetron in Treatment Resistant Obsessive Compulsive Disorder (OCD) Completed NCT00796497 Phase 4 ondansetron
16 Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder Completed NCT00723060 Phase 4 escitalopram
17 Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Practical Trial Completed NCT00680602 Phase 4 SSRI (fluoxetine, sertraline, paroxetine, citalopram)
18 Quetiapine Augmentation Versus Clomipramine Augmentation of SSRI for Obsessive-compulsive Disorder Patients Completed NCT00564564 Phase 4 Quetiapine;Clomipramine
19 Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment Completed NCT00466609 Phase 4 Clomipramine (fluoxetine plus clomipramine);Quetiapine (fluoxetine plus quetiapine);Placebo (fluoxetine plus placebo)
20 Duloxetine for the Treatment of Obsessive Compulsive Disorder (OCD) Completed NCT00464698 Phase 4 Duloxetine
21 Effectiveness of Sertraline and Cognitive Behavioral Therapy in Treating Pediatric Obsessive-Compulsive Disorder Completed NCT00382291 Phase 4 Regular Titration;Placebo;Slow Titration
22 Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder Completed NCT00211744 Phase 4 topiramate
23 Escitalopram for the Treatment of Obsessive Compulsive Disorder (OCD) Completed NCT00116532 Phase 4 Escitalopram
24 Treatment of Obsessive-Compulsive Disorder Completed NCT00000373 Phase 4 olanzapine + fluoxetine;placebo + fluoxetine
25 Multimodal Treatment Study of Children With Attention Deficit and Hyperactivity Disorder (MTA) Completed NCT00000388 Phase 4 Anti-ADHD medication
26 Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated With Streptococcal Infections Completed NCT00001658 Phase 4 Amoxicillin
27 Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
28 Developing New Clinical Management Strategies Completed NCT02082392 Phase 4 Escitalopram
29 Treatment Trial for Psychogenic Nonepileptic Seizures Completed NCT00835627 Phase 4 sertraline
30 Treatments for Psychogenic Nonepileptic Seizures (NES) Completed NCT00159965 Phase 4 sertraline;placebo
31 Fear Conditioned Response in Healthy Subjects and in OCD Patients Pre and Post Treatment With Sertraline. Recruiting NCT03068429 Phase 4 Sertraline Hydrochloride
32 Probiotic Treatment in Adult Obsessive-Compulsive Disorder Recruiting NCT02334644 Phase 4
33 A Study of Pregabalin (Lyrica) Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive Compulsive Disorder Recruiting NCT00994786 Phase 4 pregabalin;Placebo
34 Efficacy of Adding Topiramate to Current Treatment in Refractory Obsessive Compulsive Disorder (OCD) Recruiting NCT00182520 Phase 4 Topiramate;placebo
35 Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients Recruiting NCT02022709 Phase 4 Fluoxetine;Sertraline;Paroxetine;Citalopram;Fluvoxamine
36 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders Recruiting NCT03239210 Phase 4 Ondansetron;Placebo
37 Translational Approach to the Understanding and Treatment of Obsessive-Compulsive Disorder (OCD). Can D-Cycloserine Enhance and Stabilize the Treatment-response in Relapsed and Non-responding OCD-patients? Active, not recruiting NCT02656342 Phase 4 D-Cycloserine;Placebo
38 Brief Intervention for OCD Fears Suspended NCT02790710 Phase 4 Propanolol;Placebo
39 Pharmacology of Cognition in Schizotypal Personality Disorder Terminated NCT00353379 Phase 4 Guanfacine;Placebo
40 Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order Terminated NCT00282165 Phase 4 naratriptan;placebo
41 Fluvoxamine Maleate in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents Terminated NCT00352768 Phase 4 Fluvoxamine maleate;Placebo
42 Fluoxetine for Obsessive-Compulsive Disorder in Children and Adolescents With Bipolar Disorder Terminated NCT00592852 Phase 4 fluoxetine
43 Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders Terminated NCT00182533 Phase 4 Sertraline;Placebo
44 Cipralex in Treatment of Depressive Symptoms and Chronic Back Pain Withdrawn NCT00227292 Phase 4 Escitalopram;Placebo
45 Safety and Effectiveness of Capsulotomy in Refractory OCD Unknown status NCT02375152 Phase 2, Phase 3
46 Novel Deep Brain Stimulation in Ventral Capsule and Stratum for Refractory Obsessive-Compulsive Disorder Unknown status NCT02590445 Phase 2, Phase 3
47 BOSCOT : A Randomised Controlled Trial of Cognitive Behavioural Therapy in Borderline Personality Disorder Completed NCT00538135 Phase 3
48 Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD) Completed NCT00880919 Phase 3 quetiapine extended-release;Placebo
49 Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder Completed NCT01912391 Phase 3 Selegiline;Placebo (for Selegiline)
50 Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder Completed NCT00122070 Phase 3 Quetiapine Fumarate

Search NIH Clinical Center for Personality Disorder

Genetic Tests for Personality Disorder

Genetic tests related to Personality Disorder:

# Genetic test Affiliating Genes
1 Personality Disorder 29

Anatomical Context for Personality Disorder

MalaCards organs/tissues related to Personality Disorder:

41
Brain, Testes, Amygdala, Eye, Cortex, Heart, Pituitary

Publications for Personality Disorder

Articles related to Personality Disorder:

(show top 50) (show all 4249)
# Title Authors Year
1
Impulsivity and its association with childhood trauma experiences across bipolar disorder, attention deficit hyperactivity disorder and borderline personality disorder. ( 30336349 )
2019
2
Psychotic symptoms in borderline personality disorder: an update. ( 30169467 )
2019
3
Borderline personality disorder traits and suicide risk: The mediating role of insomnia and nightmares. ( 30326346 )
2019
4
Diagnosis and classification of personality disorders: novel approaches. ( 30234525 )
2019
5
Trace elements among a sample of prisoners with mental and personality disorders and aggression: correlation with impulsivity and ADHD indices. ( 30466921 )
2019
6
Exclusion-Proneness in Borderline Personality Disorder Inpatients Impairs Alliance in Mentalization-Based Group Therapy. ( 29910754 )
2018
7
Frontal and temporal cortical volume, white matter tract integrity, and hemispheric asymmetry in schizotypal personality disorder. ( 29454512 )
2018
8
Change in Biased Thinking in a Treatment Based on the Motive-Oriented Therapeutic Relationship for Borderline Personality Disorder. ( 29388899 )
2018
9
Positive psychotic symptoms in patients with borderline personality disorder: a valuable but still not completely understood clinical marker of the illness. ( 29873564 )
2018
10
The effect of methylphenidate on decision making in patients with borderline personality disorder and attention-deficit/hyperactivity disorder. ( 29847836 )
2018
11
Individuals with Borderline Personality Disorder manifest cognitive biases implicated in psychosis. ( 29960939 )
2018
12
Sensitization of the Neural Salience Network to Repeated Emotional Stimuli Following Initial Habituation in Patients With Borderline Personality Disorder. ( 29961363 )
2018
13
Relationships Among Avoidant Personality Disorder, Social Anxiety Disorder, and Normative Personality Traits: A Twin Study. ( 29505386 )
2018
14
Training in Good Psychiatric Management for Borderline Personality Disorder in Residency: An Aide to Learning Supportive Psychotherapy for Challenging-to-Treat Patients. ( 29809114 )
2018
15
Personality Constructs and Paradigms in the Alternative DSM-5 Model of Personality Disorder. ( 29902081 )
2018
16
Episodic memory and consciousness in antisocial personality disorder and conduct disorder. ( 29353574 )
2018
17
Maternal personality disorder symptoms in primary health care: associations with mother-toddler interactions at one-year follow-up. ( 29914432 )
2018
18
On the potential for iatrogenic effects of psychiatric crisis services: The example of dialectical behavior therapy for adult women with borderline personality disorder. ( 29369662 )
2018
19
Erratum - Borderline Personality Disorder Symptom Severity and Sexually Transmitted Infection and HIV Risk in African American Incarcerated Men. ( 29889162 )
2018
20
Borderline personality disorder is equally trait-like and state-like over ten years in adult psychiatric patients. ( 29952598 )
2018
21
Behavioural mimicry and loneliness in borderline personality disorder. ( 29407356 )
2018
22
The Endocannabinoid System, Aggression, and the Violence of Synthetic Cannabinoid Use, Borderline Personality Disorder, Antisocial Personality Disorder, and Other Psychiatric Disorders. ( 29636670 )
2018
23
Variability in phase and amplitude of diurnal rhythms is related to variation of mood in bipolar and borderline personality disorder. ( 29374207 )
2018
24
Abnormal Sensitization of Neural and Behavioral Responses to Socially Relevant Images in Individuals With Borderline Personality Disorder: Implications for Guiding More Effective Targeting of Treatments. ( 29961366 )
2018
25
What influences social outcomes among offenders with personality disorder: A systematic review. ( 29920809 )
2018
26
Psychosocial stress differentially affects emotional empathy in women with borderline personality disorder and healthy controls. ( 29417987 )
2018
27
Differential relations of executive functioning to borderline personality disorder presentations in adolescents. ( 29388349 )
2018
28
Shining lights in dark corners of people's lives: Reaching consensus for people with complex mental health difficulties who are given a diagnosis of personality disorder. ( 29417661 )
2018
29
Transient hallucinations during interpersonal stress in an adolescent with borderline personality disorder. ( 29374970 )
2018
30
Perimenstrual exacerbation of symptoms in borderline personality disorder: evidence from multilevel models and the Carolina Premenstrual Assessment Scoring System. ( 29860953 )
2018
31
Dissecting the elements of borderline personality disorder. ( 29878704 )
2018
32
Continuity between DSM-5 Section II and Section III personality traits for obsessive-compulsive personality disorder. ( 29024130 )
2018
33
Fear of Being Laughed at in Borderline Personality Disorder. ( 29410640 )
2018
34
Enhanced mental imagery and intact perceptual organization in schizotypal personality disorder. ( 29131991 )
2018
35
Quasi-psychosis in covert Narcissistic Personality Disorder-A case report. ( 29272784 )
2018
36
Does Religiosity Reduce Narcissistic Personality Disorder? Examining the Case of Muslim University Students. ( 29691791 )
2018
37
Alliance Rupture and Resolution in Dialectical Behavior Therapy for Borderline Personality Disorder. ( 29388901 )
2018
38
Improving functional outcomes in women with borderline personality disorder and PTSD by changing PTSD severity and post-traumatic cognitions. ( 29448136 )
2018
39
Borderline personality disorder and sexual abuse: A systematic review. ( 29407572 )
2018
40
Psychiatrists' motives for practising in-patient compulsory care of patients with borderline personality disorder (BPD). ( 29853014 )
2018
41
Stability of the Pregnancy Obsessive-Compulsive Personality Disorder Symptoms Checklist. ( 29067550 )
2018
42
Features of borderline personality disorder as a mediator of the relation between childhood traumatic experiences and psychosis-like experiences in patients with mood disorder. ( 29353179 )
2018
43
Clinical Components of Borderline Personality Disorder and Personality Functioning. ( 29393279 )
2018
44
Movies in Mind: 'We need to talk about Kevin'-Is an antisocial personality disorder 'born' or 'made'? ( 29676160 )
2018
45
Bruno Klopfer Award Address: Five-Factor Model Personality Disorder Scales. ( 29897255 )
2018
46
Examining the alternative model for personality disorder in daily life: Evidence for incremental validity. ( 29927292 )
2018
47
Examining the DSM-5 alternative model of personality disorders operationalization of obsessive-compulsive personality disorder in a mental health sample. ( 29927297 )
2018
48
Treatment of a Patient with Borderline Personality Disorder Based on Phase-Oriented Model of Eye Movement Desensitization and Reprocessing (EMDR): A Case Report. ( 29892320 )
2018
49
The Role of Negative Affect and Self-Concept Clarity in Predicting Self-Injurious Urges in Borderline Personality Disorder Using Ecological Momentary Assessment. ( 29388895 )
2018
50
Construct Validity of the McLean Screening Instrument for Borderline Personality Disorder in Two Singaporean Samples. ( 29949444 )
2018

Variations for Personality Disorder

Expression for Personality Disorder

Search GEO for disease gene expression data for Personality Disorder.

Pathways for Personality Disorder

Pathways related to Personality Disorder according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.35 AVPR1A DRD2 DRD4 HTR1A HTR1B HTR2A
2
Show member pathways
12.83 COMT DRD2 DRD4 MAOA SLC6A3
3
Show member pathways
12.81 ALDH2 COMT MAOA SLC6A3 SLC6A4
5
Show member pathways
12.1 BDNF DRD2 HTR1A HTR1B
6 12.01 BDNF HTR1A HTR2A MAOA SLC6A4 TPH1
7
Show member pathways
11.8 BDNF DRD2 MAOA SLC6A3
8
Show member pathways
11.79 DRD2 DRD4 HTR1A HTR1B HTR2A HTR2C
9 11.64 DRD2 HTR2A HTR2C
10 11.56 HTR1A HTR1B HTR2A HTR2C MAOA SLC6A4
11
Show member pathways
11.27 MAOA SLC6A3 SLC6A4
12
Show member pathways
10.97 ALDH2 COMT MAOA SLC6A3 SLC6A4
13
Show member pathways
10.92 COMT MAOA TPH1
14 10.88 HTR2A HTR2C
15
Show member pathways
10.72 ALDH2 COMT MAOA
16 10.69 COMT MAOA
17
Show member pathways
10.65 ALDH2 MAOA
18 10.61 HTR1A HTR1B HTR2A HTR2C MAOA SLC6A4

GO Terms for Personality Disorder

Cellular components related to Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.91 AVPR1A DRD2 DRD4 HTR1A HTR1B HTR2A
2 axon GO:0030424 9.77 BDNF COMT DRD2 HTR2A SLC6A3
3 integral component of postsynaptic membrane GO:0099055 9.46 DRD2 HTR2A SLC6A3 SLC6A4
4 dopaminergic synapse GO:0098691 9.4 DRD2 SLC6A3
5 integral component of presynaptic membrane GO:0099056 9.35 DRD2 HTR1B HTR2A SLC6A3 SLC6A4
6 serotonergic synapse GO:0099154 9.32 HTR1B SLC6A4
7 dendrite GO:0030425 9.23 BDNF COMT DRD2 DRD4 HTR1A HTR1B
8 integral component of membrane GO:0016021 10.17 AVPR1A COMT DRD2 DRD4 HTR1A HTR1B

Biological processes related to Personality Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.91 DRD4 HTR1A HTR1B HTR2A HTR2C
2 response to organic cyclic compound GO:0014070 9.89 COMT PRL SLC6A3
3 cellular calcium ion homeostasis GO:0006874 9.86 DRD4 HTR2A HTR2C
4 locomotory behavior GO:0007626 9.86 DRD2 HTR2C SLC6A3
5 circadian rhythm GO:0007623 9.85 PRL SLC6A4 TPH1
6 memory GO:0007613 9.84 BDNF HTR2A SLC6A4
7 response to ethanol GO:0045471 9.84 DRD2 HTR1B PRL SLC6A3
8 social behavior GO:0035176 9.81 AVPR1A DRD4 SLC6A4
9 positive regulation of fat cell differentiation GO:0045600 9.81 HTR2A HTR2C TPH1
10 regulation of synaptic vesicle exocytosis GO:2000300 9.8 DRD2 HTR1B HTR2A
11 release of sequestered calcium ion into cytosol GO:0051209 9.78 DRD2 HTR2A HTR2C
12 response to cocaine GO:0042220 9.77 DRD2 HTR1B SLC6A3
13 feeding behavior GO:0007631 9.74 DRD2 HTR1B HTR2C
14 behavioral fear response GO:0001662 9.73 DRD4 HTR1A HTR2C
15 arachidonic acid secretion GO:0050482 9.72 DRD2 DRD4
16 temperature homeostasis GO:0001659 9.72 DRD2 HTR2A
17 activation of phospholipase C activity GO:0007202 9.72 AVPR1A BDNF HTR2A
18 positive regulation of kinase activity GO:0033674 9.71 DRD4 HTR2A
19 dopamine receptor signaling pathway GO:0007212 9.71 DRD2 DRD4
20 negative regulation of protein secretion GO:0050709 9.71 DRD2 DRD4
21 response to iron ion GO:0010039 9.7 DRD2 SLC6A3
22 bone remodeling GO:0046849 9.7 HTR1B TPH1
23 prepulse inhibition GO:0060134 9.7 DRD2 SLC6A3
24 grooming behavior GO:0007625 9.7 AVPR1A DRD2
25 neurotransmitter biosynthetic process GO:0042136 9.69 SLC6A3 SLC6A4
26 positive regulation of renal sodium excretion GO:0035815 9.69 AVPR1A DRD2
27 G protein-coupled receptor internalization GO:0002031 9.68 DRD2 HTR1B
28 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.68 DRD2 DRD4
29 catecholamine metabolic process GO:0006584 9.67 COMT MAOA
30 neurotransmitter catabolic process GO:0042135 9.67 COMT MAOA
31 regulation of behavior GO:0050795 9.67 HTR1A HTR1B
32 behavioral response to cocaine GO:0048148 9.67 DRD2 DRD4 HTR2A
33 adenohypophysis development GO:0021984 9.66 DRD2 SLC6A3
34 behavioral response to ethanol GO:0048149 9.65 DRD2 DRD4
35 monoamine transport GO:0015844 9.65 SLC6A3 SLC6A4
36 negative regulation of voltage-gated calcium channel activity GO:1901386 9.65 DRD2 DRD4
37 vasoconstriction GO:0042310 9.65 HTR1A HTR1B SLC6A4
38 drinking behavior GO:0042756 9.64 DRD2 HTR1B
39 sperm ejaculation GO:0042713 9.63 AVPR1A SLC6A4
40 dopamine metabolic process GO:0042417 9.63 COMT DRD2 DRD4
41 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.61 HTR2A HTR2C
42 regulation of dopamine metabolic process GO:0042053 9.61 DRD4 HTR1A SLC6A3
43 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.59 HTR1A HTR1B
44 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.58 DRD2 DRD4
45 response to histamine GO:0034776 9.58 DRD2 DRD4
46 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.58 DRD2 HTR1B HTR2A
47 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.56 DRD4 HTR1A HTR1B HTR2A
48 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.55 DRD4 HTR1A HTR1B HTR2A HTR2C
49 serotonin receptor signaling pathway GO:0007210 9.54 HTR1A HTR2A HTR2C
50 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.52 HTR2A HTR2C

Molecular functions related to Personality Disorder according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.91 AVPR1A DRD2 DRD4 HTR1A HTR1B HTR2A
2 neurotransmitter receptor activity GO:0030594 9.65 DRD4 HTR1A HTR1B HTR2A HTR2C
3 G protein-coupled serotonin receptor activity GO:0004993 9.55 DRD4 HTR1A HTR1B HTR2A HTR2C
4 dopamine binding GO:0035240 9.5 DRD2 DRD4 SLC6A3
5 neurotransmitter:sodium symporter activity GO:0005328 9.49 SLC6A3 SLC6A4
6 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.48 DRD2 DRD4
7 monoamine transmembrane transporter activity GO:0008504 9.46 SLC6A3 SLC6A4
8 dopamine neurotransmitter receptor activity GO:0004952 9.43 DRD2 DRD4
9 drug binding GO:0008144 9.43 DRD2 DRD4 HTR1B HTR2A HTR2C SLC6A3
10 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.4 HTR2A HTR2C
11 serotonin binding GO:0051378 9.02 HTR1A HTR1B HTR2A HTR2C SLC6A4

Sources for Personality Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....